Trending Stock News

New York & Co (NWY) Shareholder North Run Capital LP Cut Position as Stock Value Rose; Ironwood Pharmaceuticals (IRWD) Holder Brown Capital Management Has Boosted Stake

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Thomas Ellis decreased its stake in New York & Co Inc (NWY) by 45.38% based on its latest 2017Q4 regulatory filing with the SEC. North Run Capital Lp sold 748,149 shares as the company’s stock rose 25.00% while stock markets declined. The hedge fund run by Thomas Ellis held 900,351 shares of the consumer services company at the end of 2017Q4, valued at $2.58 million, down from 1.65 million at the end of the previous reported quarter. North Run Capital Lp who had been investing in New York & Co Inc for a number of months, seems to be less bullish one the $255.68 million market cap company. The stock decreased 0.25% or $0.01 during the last trading session, reaching $3.99. About 149,676 shares traded. New York & Company, Inc. (NYSE:NWY) has risen 75.26% since April 29, 2017 and is uptrending. It has outperformed by 63.71% the S&P500.

Brown Capital Management Llc increased its stake in Ironwood Pharmaceuticals Inc (IRWD) by 0.74% based on its latest 2017Q4 regulatory filing with the SEC. Brown Capital Management Llc bought 46,250 shares as the company’s stock declined 1.30% with the market. The institutional investor held 6.26 million shares of the health care company at the end of 2017Q4, valued at $93.90M, up from 6.22 million at the end of the previous reported quarter. Brown Capital Management Llc who had been investing in Ironwood Pharmaceuticals Inc for a number of months, seems to be bullish on the $2.82 billion market cap company. The stock increased 7.11% or $1.24 during the last trading session, reaching $18.68. About 2.26 million shares traded or 63.71% up from the average. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 11.53% since April 29, 2017 and is downtrending. It has underperformed by 23.08% the S&P500.

Brown Capital Management Llc, which manages about $7.02 billion and $8.24B US Long portfolio, decreased its stake in Blackbaud Inc (NASDAQ:BLKB) by 387,829 shares to 4.50 million shares, valued at $425.52M in 2017Q4, according to the filing. It also reduced its holding in Meridian Bioscience Inc (NASDAQ:VIVO) by 828,323 shares in the quarter, leaving it with 4.67M shares, and cut its stake in Abaxis Inc (NASDAQ:ABAX).

Investors sentiment decreased to 1.05 in 2017 Q4. Its down 0.20, from 1.25 in 2017Q3. It is negative, as 18 investors sold IRWD shares while 44 reduced holdings. 21 funds opened positions while 44 raised stakes. 149.98 million shares or 2.99% less from 154.60 million shares in 2017Q3 were reported. Raymond James Finance Services Advsrs Incorporated holds 0% or 11,483 shares in its portfolio. Principal Financial Grp Inc owns 43,054 shares. Orbimed Advsr Limited Liability stated it has 0.86% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Great West Life Assurance Can owns 14,842 shares or 0% of their US portfolio. Chicago Equity Prns Ltd Limited Liability Company holds 213,680 shares or 0.1% of its portfolio. Susquehanna Group Inc Ltd Liability Partnership owns 12,583 shares for 0% of their portfolio. Penn Cap Mngmt Communications has invested 0.9% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Platinum Inv Limited reported 104,500 shares or 0.04% of all its holdings. Td Asset Management Inc holds 331,601 shares. Blackrock has invested 0.01% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Strs Ohio invested in 0% or 500 shares. Pictet Asset Mngmt Limited, a United Kingdom-based fund reported 2.99M shares. Proshare Ltd Liability Corp reported 92,936 shares. Geode Mngmt Ltd Llc has 1.24M shares. Evercore Wealth Mgmt Limited Liability Company holds 0.01% or 22,425 shares in its portfolio.

Since January 24, 2018, it had 0 buys, and 7 selling transactions for $1.22 million activity. Another trade for 1,500 shares valued at $21,090 was sold by McHugh Julie. On Wednesday, February 21 the insider Consylman Gina sold $52,688. OLANOFF LAWRENCE S sold $28,100 worth of stock or 2,000 shares. $49,008 worth of stock was sold by MCCOURT Thomas A on Wednesday, February 21. 7,741 shares were sold by Gilbert Halley E, worth $113,483.

Among 16 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 5 have Buy rating, 2 Sell and 9 Hold. Therefore 31% are positive. Ironwood Pharmaceuticals had 39 analyst reports since August 6, 2015 according to SRatingsIntel. As per Monday, August 10, the company rating was downgraded by Zacks. J.P. Morgan downgraded the stock to “Hold” rating in Friday, July 21 report. The company was maintained on Wednesday, February 22 by Barclays Capital. As per Friday, October 6, the company rating was maintained by Mizuho. As per Monday, March 12, the company rating was maintained by Mizuho. The firm has “Buy” rating by Mizuho given on Friday, November 4. The stock has “Neutral” rating by Wedbush on Thursday, April 28. The firm has “Buy” rating by Cowen & Co given on Wednesday, November 1. Goldman Sachs initiated the shares of IRWD in report on Monday, March 21 with “Neutral” rating. WallachBeth Capital maintained it with “Hold” rating and $17 target in Tuesday, September 27 report.

Investors sentiment increased to 1.05 in 2017 Q4. Its up 0.21, from 0.84 in 2017Q3. It improved, as 5 investors sold NWY shares while 14 reduced holdings. 12 funds opened positions while 8 raised stakes. 21.11 million shares or 0.87% more from 20.93 million shares in 2017Q3 were reported. Moreover, Millennium Lc has 0% invested in New York & Company, Inc. (NYSE:NWY) for 21,745 shares. 671,564 were accumulated by Putnam Investments Limited Com. Deutsche National Bank Ag holds 0% of its portfolio in New York & Company, Inc. (NYSE:NWY) for 36,492 shares. New York-based Goldman Sachs Group has invested 0% in New York & Company, Inc. (NYSE:NWY). Geode Mngmt Lc holds 0% of its portfolio in New York & Company, Inc. (NYSE:NWY) for 158,300 shares. Connor Clark And Lunn Mngmt holds 0% or 28,577 shares in its portfolio. Gsa Ltd Liability Partnership reported 0.01% in New York & Company, Inc. (NYSE:NWY). Prelude Ltd Liability has invested 0% in New York & Company, Inc. (NYSE:NWY). Acadian Asset Management Limited Liability Co holds 0% of its portfolio in New York & Company, Inc. (NYSE:NWY) for 14,195 shares. Eam Invsts Llc stated it has 0.06% in New York & Company, Inc. (NYSE:NWY). Quinn Opportunity Prtn Limited Liability Company invested in 45,353 shares or 0.02% of the stock. North Run Capital Lp invested in 1.57% or 900,351 shares. 11,290 were reported by Panagora Asset Management. Citigroup Incorporated has invested 0% of its portfolio in New York & Company, Inc. (NYSE:NWY). Renaissance Ltd Co owns 1.24 million shares.

Among 2 analysts covering New York & Company (NYSE:NWY), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. New York & Company had 4 analyst reports since August 15, 2015 according to SRatingsIntel. Zacks downgraded the stock to “Buy” rating in Tuesday, August 25 report. The rating was downgraded by Wunderlich to “Hold” on Friday, May 20. Roth Capital initiated the shares of NWY in report on Monday, April 2 with “Buy” rating. The firm earned “Buy” rating on Saturday, August 15 by Wunderlich.

Since April 6, 2018, it had 1 buying transaction, and 1 insider sale for $298,517 activity. 3,400 shares were bought by Worthington John M, worth $13,566.

North Run Capital Lp, which manages about $1.78B and $163.67M US Long portfolio, upped its stake in New York Reit Inc (NYSE:NYRT) by 1.00M shares to 3.63 million shares, valued at $14.25M in 2017Q4, according to the filing.

New York & Company, Inc. (NYSE:NWY) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *